Synlogic Achieves Milestone in Development of Synthetic Biotic for IBD

March 7, 2019

Synlogic, Inc (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced on 3/6/19 the advancement of Synthetic Biotic medicines to the lead optimization stage in its collaboration with AbbVie, a global biopharmaceutical company, to develop an oral treatment for inflammatory bowel disease (IBD).

“We are delighted with the progress of our collaboration with AbbVie, a world-class company with expertise in immunology and the development of treatments for patients with inflammatory bowel disease,” said Aoife Brennan, M.B, Ch.B., Synlogic’s president and chief executive officer “Our collaboration has enabled us to broaden the reach of our platform in inflammatory and autoimmune conditions while advancing our internal pipeline in rare metabolic diseases.”

The company currently has five candidates in development, including an oncology program.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.